Advanced search
Publication Cover
Expert Review of Hematology Volume 6, 2013 - Issue 1
Submit an article Journal homepage
81
Views
13
CrossRef citations to date
0
Altmetric
Review

The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?

Zaher K Otrock Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
,
Ramon V Tiu Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
,
Jaroslaw P Maciejewski Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
&
Mikkael A Sekeres Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA. [email protected]
Pages 59-68 | Published online: 10 Jan 2014

References

  • Malcovati L, Nimer SD. Myelodysplastic syndromes: diagnosis and staging. Cancer Control 15(Suppl), 4–13 (2008).
  • Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin. Proc. 81(1), 104–130 (2006).
  • Sekeres MA. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J. Natl Compr. Canc. Netw. 9(1), 57–63 (2011).
  • Maynadié M, Verret C, Moskovtchenko P et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br. J. Cancer 74(2), 288–290 (1996).
  • Phekoo KJ, Richards MA, Møller H, Schey SA; South Thames Haematology Specialist Committee. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica 91(10), 1400–1404 (2006).
  • Rådlund A, Thiede T, Hansen S, Carlsson M, Engquist L. Incidence of myelodysplastic syndromes in a Swedish population. Eur. J. Haematol. 54(3), 153–156 (1995).
  • Neukirchen J, Schoonen WM, Strupp C et al. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk. Res. 35(12), 1591–1596 (2011).
  • Rollison DE, Howlader N, Smith MT et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 112(1), 45–52 (2008).
  • Strom SS, Gu Y, Gruschkus SK, Pierce SA, Estey EH. Risk factors of myelodysplastic syndromes: a case–control study. Leukemia 19(11), 1912–1918 (2005).
  • Du Y, Fryzek J, Sekeres MA, Taioli E. Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). Leuk. Res. 34(1), 1–5 (2010).
  • Sekeres MA. Are we nearer to curing patients with MDS? Best Pract. Res. Clin. Haematol. 23(4), 481–487 (2010).
  • Steensma DP, List AF. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin. Proc. 80(5), 681–698 (2005).
  • Sekeres MA, Schoonen WM, Kantarjian H et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J. Natl Cancer Inst. 100(21), 1542–1551 (2008).
  • Golshayan AR, Jin T, Maciejewski J et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br. J. Haematol. 137(2), 125–132 (2007).
  • Jädersten M, Malcovati L, Dybedal I et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J. Clin. Oncol. 26(21), 3607–3613 (2008).
  • List A, Dewald G, Bennett J et al.; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355(14), 1456–1465 (2006).
  • Komrokji RS, Sekeres MA, List AF. Management of lower-risk myelodysplastic syndromes: the art and evidence. Curr. Hematol. Malig. Rep. 6(2), 145–153 (2011).
  • Dobbelstein C, Ganser A. Immunosuppressive therapy for myelodysplastic syndromes. Curr. Pharm. Des. 18(22), 3184–3189 (2012).
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al.; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, Phase III study. Lancet Oncol. 10(3), 223–232 (2009).
  • Lübbert M, Suciu S, Baila L et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized Phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J. Clin. Oncol. 29(15), 1987–1996 (2011).
  • Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer 106(8), 1794–1803 (2006).
  • Ornstein MC, Sekeres MA. Combination strategies in myelodysplastic syndromes. Int. J. Hematol. 95(1), 26–33 (2012).
  • Kawankar N, Vundinti BR. Cytogenetic abnormalities in myelodysplastic syndrome: an overview. Hematology 16(3), 131–138 (2011).
  • Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6), 2079–2088 (1997).
  • Kantarjian H, O’Brien S, Ravandi F et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113(6), 1351–1361 (2008).
  • Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12), 2454–2465 (2012).
  • Slovak ML, Dewald GW. International Working Group on MDS cytogenetics: October 2007 meeting report. Leuk Res 32(9), 1329–1332 (2008).
  • Steidl C, Steffens R, Gassmann W et al. Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. Leuk. Res. 29(9), 987–993 (2005).
  • ShafferLG, SlovakML, CampbellLJ (Eds). An International System for Human Cytogenetic Nomenclature (2009): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Karger, Basel, Switzerland (2009).
  • Haase D, Germing U, Schanz J et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110(13), 4385–4395 (2007).
  • Solé F, Luño E, Sanzo C et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 90(9), 1168–1178 (2005).
  • Schanz J, Steidl C, Fonatsch C et al. Coalesced multicentric analysis of 2351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J. Clin. Oncol. 29(15), 1963–1970 (2011).
  • Schanz J, Tüchler H, Solé F et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J. Clin. Oncol. 30(8), 820–829 (2012).
  • Pardanani A, Tefferi A. Cytogenetic risk stratification in myelodysplastic syndromes: are we there yet? J. Clin. Oncol. 30(21), 2703–2704; author reply 2704 (2012).
  • Bejar R, Stevenson K, Abdel-Wahab O et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364(26), 2496–2506 (2011).
  • Tiu RV, Gondek LP, O’Keefe CL et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 117(17), 4552–4560 (2011).
  • Gondek LP, Tiu R, O’Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111(3), 1534–1542 (2008).
  • Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J. Clin. Oncol. 29(5), 504–515 (2011).
  • Mohamedali A, Gäken J, Twine NA et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 110(9), 3365–3373 (2007).
  • Ketterling RP, Wyatt WA, VanWier SA et al. Primary myelodysplastic syndrome with normal cytogenetics: utility of ‘FISH panel testing’ and M-FISH. Leuk. Res. 26(3), 235–240 (2002).
  • Bernasconi P, Boni M, Cavigliano PM et al. Clinical relevance of cytogenetics in myelodysplastic syndromes. Ann. NY Acad. Sci. 1089, 395–410 (2006).
  • Skonieczka K, Duszenko E, Wyrowinska E, Haus O. Usefulness of classic cytogenetic testing compared to fluorescence in situ hybridization in genetic diagnosis of 58 patients with myelodysplastic syndromes. Pol. Arch. Med. Wewn. 119(6), 366–372 (2009).
  • Chen L, Li J, Zhu Y et al. Conventional and molecular cytogenetic features of myelodysplastic syndrome in China. Exp. Oncol. 29(4), 299–303 (2007).
  • Makishima H, Rataul M, Gondek LP et al. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). Leuk. Res. 34(4), 447–453 (2010).
  • Maciejewski JP, Tiu RV, O’Keefe C. Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies. Br. J. Haematol. 146(5), 479–488 (2009).
  • Mantripragada KK, Buckley PG, Diaz de Ståhl T, Dumanski JP. Genomic microarrays in the spotlight. Trends Genet. 20(2), 87–94 (2004).
  • O’Keefe CL, Tiu R, Gondek LP et al. High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. Exp. Hematol. 35(2), 240–251 (2007).
  • Thiel A, Beier M, Ingenhag D et al. Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance. Leukemia 25(3), 387–399 (2011).
  • Kolquist KA, Schultz RA, Furrow A et al. Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes. Cancer Genet. 204(11), 603–628 (2011).
  • Slovak ML, Smith DD, Bedell V et al. Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes. Mol. Cytogenet. 3, 23 (2010).
  • Starczynowski DT, Vercauteren S, Telenius A et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 112(8), 3412–3424 (2008).
  • Tan DS, Lambros MB, Natrajan R, Reis-Filho JS. Getting it right: designing microarray (and not ‘microawry’) comparative genomic hybridization studies for cancer research. Lab. Invest. 87(8), 737–754 (2007).
  • Jacoby MA, Walter MJ. Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes. Expert Rev. Mol. Diagn. 12(3), 253–264 (2012).
  • Gondek LP, Haddad AS, O’Keefe CL et al. Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Exp. Hematol. 35(11), 1728–1738 (2007).
  • Kosmider O, Gelsi-Boyer V, Cheok M et al.; Groupe Francophone des Myélodysplasies. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 114(15), 3285–3291 (2009).
  • Langemeijer SM, Kuiper RP, Berends M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41(7), 838–842 (2009).
  • Itzykson R, Kosmider O, Cluzeau T et al.; Groupe Francophone des Myelodysplasies (GFM). Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25(7), 1147–1152 (2011).
  • Smith AE, Mohamedali AM, Kulasekararaj A et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 116(19), 3923–3932 (2010).
  • Harada Y, Harada H. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations. J. Cell. Physiol. 220(1), 16–20 (2009).
  • Harada Y, Harada H. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations. J. Cell. Biochem. 112(2), 425–432 (2011).
  • Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 104(5), 1474–1481 (2004).
  • Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103(6), 2316–2324 (2004).
  • Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur. J. Haematol. 74(1), 47–53 (2005).
  • Fisher CL, Randazzo F, Humphries RK, Brock HW. Characterization of Asxl1, a murine homolog of additional sex combs, and analysis of the Asx-like gene family. Gene 369, 109–118 (2006).
  • Boultwood J, Perry J, Pellagatti A et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 24(5), 1062–1065 (2010).
  • Thol F, Friesen I, Damm F et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J. Clin. Oncol. 29(18), 2499–2506 (2011).
  • Kosmider O, Gelsi-Boyer V, Slama L et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 24(5), 1094–1096 (2010).
  • Nikoloski G, Langemeijer SM, Kuiper RP et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42(8), 665–667 (2010).
  • Makishima H, Jankowska AM, Tiu RV et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 24(10), 1799–1804 (2010).
  • Xu F, Li X, Wu L et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann. Hematol. 90(6), 643–653 (2011).
  • Bejar R, Stevenson KE, Caughey BA et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J. Clin. Oncol. 30(27), 3376–3382 (2012).
  • Walter MJ, Ding L, Shen D et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25(7), 1153–1158 (2011).
  • Thol F, Winschel C, Lüdeking A et al. Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica 96(12), 1870–1873 (2011).
  • Nau MM, Lipkowitz S. Comparative genomic organization of the cbl genes. Gene 308, 103–113 (2003).
  • Makishima H, Cazzolli H, Szpurka H et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J. Clin. Oncol. 27(36), 6109–6116 (2009).
  • Kao HW, Sanada M, Liang DC et al. A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia. Neoplasia 13(11), 1035–1042 (2011).
  • Rocquain J, Carbuccia N, Trouplin V et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 10, 401 (2010).
  • Thol F, Weissinger EM, Krauter J et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95(10), 1668–1674 (2010).
  • Pardanani A, Patnaik MM, Lasho TL et al. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia 24(7), 1370–1372 (2010).
  • Patnaik MM, Hanson CA, Hodnefield JM et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia 26(1), 101–105 (2012).
  • Yoshida K, Sanada M, Shiraishi Y et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478(7367), 64–69 (2011).
  • Visconte V, Makishima H, Maciejewski JP, Tiu RV. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia 26(12):2447–2454 (2012).
  • Makishima H, Visconte V, Sakaguchi H et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 119(14), 3203–3210 (2012).
  • Papaemmanuil E, Cazzola M, Boultwood J et al.; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365(15), 1384–1395 (2011).
  • Patnaik MM, Lasho TL, Hodnefield JM et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 119(2), 569–572 (2012).
  • Bennett JM. A comparative review of classification systems in myelodysplastic syndromes (MDS). Semin. Oncol. 32(4 Suppl. 5), S3–S10 (2005).
  • Bowen D, Culligan D, Jowitt S et al.; UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br. J. Haematol. 120(2), 187–200 (2003).
  • Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51(2), 189–199 (1982).
  • Vardiman JW, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5), 937–951 (2009).
  • Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J. Clin. Oncol. 25(23), 3503–3510 (2007).
  • Malcovati L, Della Porta MG, Strupp C et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 96(10), 1433–1440 (2011).
  • Garcia-Manero G, Shan J, Faderl S et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22(3), 538–543 (2008).
  • Sekeres MA, Elsen P, Tiu RV et al. Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndrome. Presented at: 53rd ASH General Meeting. San Diego, CA, USA, 10–13 December 2011.
  • Gelsi-Boyer V, Trouplin V, Roquain J et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br. J. Haematol. 151(4), 365–375 (2010).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.